MoonLake nabs FDA Fast Track status for rare inflammatory disorder asset
Source: SeekingAlpha
2026-02-02 09:20:34 ET
More on MoonLake Immunotherapeutics
- MoonLake: Positive FDA Meeting Spurs Momentum Ahead Of BLA Submission
- MoonLake: Ignore The Panic, Catch The Upside
- MoonLake cut to sell at Goldman Sachs on risks to lead asset’s approval
- MoonLake surges as no additional studies are required for lead drug
- Seeking Alpha’s Quant Rating on MoonLake Immunotherapeutics
Read the full article on Seeking Alpha
For further details see:
MoonLake nabs FDA Fast Track status for rare inflammatory disorder asset
MoonLake Immunotherapeutics
NASDAQ: MLTX
MLTX Trading
-2.36% G/L:
$17.3401 Last:
327,454 Volume:
$17.75 Open:
MLTX Latest News
MLTX Stock Data
$1,003,283,878
28,454,210
3.61%
24
N/A
Biotechnology & Life Sciences
Healthcare
CH
Zug
